Health & biology · April 2026

Orforglipron

A small-molecule GLP-1 pill, cheap to make and taken any time.

The FDA approved Eli Lilly's orforglipron (Foundayo), a non-peptide GLP-1 drug with no food or water restrictions. In the 72-week ATTAIN-1 trial, patients lost 12.4% of body weight versus 0.9% on placebo.

See it in the living tree Wikipedia Source

Arcs above join it to what it stood on, arcs below to what it led to. The bar places this stretch on the tree's whole timeline.

What it built on 2

GLP-1 pill for obesity 2025
GLP-1 insulin action 1987

Related measurements

The dashed line marks when it first worked.

Life expectancy at birth Latest: 73.2 years (2023) Source: Our World in Data